Search results
Showing 136 to 150 of 379 results for lung cancer
sublobar, wedge resection, lobectomy) for people with non-small-cell lung cancer (stage I and IIA) in whom surgery is suitable? Any...
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
Brain tumours (primary) and brain metastases in over 16s (NG99)
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]
Awaiting development Reference number: GID-TA11953 Expected publication date: TBC
Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]
Awaiting development Reference number: GID-TA11977 Expected publication date: TBC
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]
Awaiting development Reference number: GID-TA11814 Expected publication date: TBC
Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]
Awaiting development Reference number: GID-TA11981 Expected publication date: TBC
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
In development Reference number: GID-IPG10448 Expected publication date: 15 October 2026
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Awaiting development Reference number: GID-TA11532 Expected publication date: TBC
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Awaiting development Reference number: GID-TA10776 Expected publication date: TBC
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]
In development Reference number: GID-TA10225 Expected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.